Table 1.
Patient and sample characteristics.
| Median (min–max) | N = 91 (%) | |
|---|---|---|
| Age | 70 (30–89) | |
| Sex | ||
| Female | 50 (55) | |
| Male | 41 (45) | |
| Cancer type | ||
| Lung | 40 (44) | |
| Breast | 24 (26) | |
| Melanoma | 6 (7) | |
| Pancreas | 4 (4) | |
| Colon | 3 (3) | |
| Rectum | 3 (3) | |
| Renal | 3 (3) | |
| Biliary | 2 (2) | |
| Stomach | 2 (2) | |
| Bladder | 2 (2) | |
| Prostate | 1 (1) | |
| Sarcoma | 1 (1) | |
| Treatment types | ||
| Chemotherapy | 32 (35) | |
| Chemotherapy, antibody | 10 (11) | |
| Immunotherapy | 24 (26) | |
| Immunotherapy, chemotherapy | 9 (10) | |
| Immunotherapy, HDACi | 1 (1) | |
| Endocrine | 4 (4) | |
| Endocrine, CDK4/6i | 6 (7) | |
| Targeted alone | 5 (5) | |
| Lines of therapy | ||
| 1 | 48 (53) | |
| 2 | 23 (25) | |
| 3+ | 20 (22) | |
| Timing (days since treatment start) | ||
| T1 | 21 (14–40) | 85 (93) |
| T2 | 42 (37–84) | 66a (72) |
| First follow-up | 69 (26–208) | |
| Last follow-up | 384 (60–754) | |
| Protocol | ||
| WGS | 53 (58) | |
| WGBS | 38b (42) | |
Abbreviation: HDACi, histone deacetylase inhibitor.
a
Sixty had both posttreatment time points.
b
In addition, 13 of the participants analyzed with WGS were also analyzed with WGBS.